4 news items
Nurix Therapeutics Announces Board Chair Transition
NRIX
20 May 24
. "Nurix is extremely fortunate to have benefited from David's exceptional guidance as chair over the last five years. His scientific and medical insight
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
NRIX
9 Apr 24
and in combination with other therapies, and the potential advantages and therapeutic benefits of NX-5948, including its potential role in the treatment
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
NRIX
2 Apr 24
to its collaboration with Gilead Sciences; the potential benefits of and Nurix's expectations with respect to the extension of the research period under
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
NRIX
11 Mar 24
previously been observed. Patients currently enrolled in the clinical study who are deriving clinical benefit from NX-2127 manufactured with the prior
- Prev
- 1
- Next